Our Corporate and Non-Profit Partners

The Power of Partnership

Our generous corporate and non-profit partners are key to the work we do. These organizations play an integral role in advancing AIM’s mission to end this disease in our lifetime while improving the lives of those it affects. We are proud to showcase the brands that partner with us. The companies and non-profits listed on this page support AIM by launching joint cause marketing campaigns, donating resoures and money, providing gifts-in-kind—or all three.  We are grateful for their support.

Men and women—young and old—develop melanoma.
Approximately 1.3 million people in the U.S. are living with melanoma. In 2024, it is estimated that 200,340 cases of melanoma will be diagnosed in the U.S.  Of those, 99,700 cases will be in situ (noninvasive), confined to the epidermis (the top layer of skin), and 100,640 cases will be invasive, penetrating the epidermis into the skin’s second layer (the dermis). The incidence rate for this disease continues to rise. When you support AIM, you support all of these people, their families, and their friends.

We invite you to join our community of corporate and non-profit partners.

Become an AIM Partner

Join us in supporting any area of our three-part mission that resonates with you: AIM provides comprehensive educational resources and support services to melanoma patients, families, and caregivers; we support melanoma patients and families in legislation, policy, and advocacy; and we manage and fund paradigm-shifting melanoma research.

AIM offers opportunities for sponsorship, cause-related marketing, corporate philanthropy, corporate social responsibility (CSR), and leadership. Creating a corporate partnership with AIM provides an excellent opportunity to demonstrate your company’s values and commitment. To learn more, contact Alicia Rowell, Vice President, or fill out the form below.

These organizations play a vital role in supporting AIM’s vision and mission to end melanoma in our lifetime.

Corporate Sponsorship Interest